$\underline{\textbf{Table S3}}$ Anti-bacterial activity of WHO recommended drugs evaluated Mtb-infected iMAC based assay

Group	Compound Name	Host-cell based assay (iMAC)	
		%Inhibition	>50% inhibition
1	Isoniazid	97.1	active
	Rifabutin	117	active
	Rifampicin	85.2	active
	Ethionamide	101.5	active
	Pyrazinamide	60	active
2	Ofloxacin	99.2	active
	Levofloxacin	109.9	active
	Gatifloxacin	108	active
	Moxifloxacin	104.9	active
3	Streptomycin sulfate	27.6	-
	Amikacin	106	active
4	Ethambutol dihydrochloride	76	active
	cycloserine	57.9	active
5	Linezolid	109.3	active
	Clofazimine	104.8	active
	Amoxicillin	62.1	active
	Clofazimine	104.8	active
	Imipenem	37.4	-
	Clarithromycin	116	active

* Foot note: Groups indicated: 1) First-line oral anti-TB drugs. 2) Fluoroquinolones. 3) Injectable anti-TB drug (injectable or parenteral agents).

4) Oral bacteriostatic second line anti-TB. 5) Anti-TB drugs with limited data on efficacy and/or long0term safety in the treatment of drug-resistant TB